Search PubMed⌕ Search

Biomedical subjects

O Tokola

Publications and source records attributed to O Tokola.

At least 37 records · Page 2Linked to original sources

Pharmacokinetics of tolfenamic acid: disposition in bile, blood and urine after intravenous administration to man.

To study its pharmacokinetics and especially microCi/100 mg was infused i.v. in 8 patients with a T-tube inserted in the common bile duct at choledocholithotomy 7-10 days prior to the study. Bile was collected in fractions by continuous suction over a 24 h period. Blood samples were taken and urine collected up to 48 h after the dose. Tolfenamic acid and its metabolites were separated by TLC and were quantitated by liquid scintillation counting. The pharmacokinetics of tolfenamic acid could be described by a two compartment open model with V1 of 3.67 +/- 0.681 and VSS of 8.0 +/- 1.01. The total plasma clearance of tolfenamic acid averaged 106 +/- 8 ml/min and t1/2 beta was 1.38 +/- 0.32 h. A three compartment open model was required to describe the kinetics of total 14C. The plasma clearance of total 14C was 15.4 +/- 3.9 ml/min and its terminal half life averaged 19.0 +/- 4.1 h. The long half-life was caused by the slow elimination of tolfenamic acid metabolites. Four metabolites were measured in plasma and bile. The principal metabolites in bile were glucuronide/sulphate conjugates of hydroxylated derivatives of tolfenamic acid. The recovery of tolfenamic acid in bile was 1.1 +/- 0.3% of the dose, whereas the recovery of total 14C was 18.6 +/- 4.9%. The biliary clearances of tolfenamic acid and total 14C were 1.2 +/- 0.3 and 5.0 +/- 2.1 ml/min, respectively. Thus, biliary excretion plays a considerable part in the pharmacokinetics of tolfenamic acid.

Aged↗

Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks.

Tolfenamic acid is a fenamate which inhibits prostaglandin (PG) biosynthesis and may act as a PG antagonist as well. Caffeine and metoclopramide are used in combination with analgesics and ergotamine in the treatment of migraine attacks, but controlled clinical studies on fixed combinations with analgesics are rare. The effects of orally given tolfenamic acid (200 mg), caffeine (100 mg), metoclopramide (10 mg), tolfenamic acid + caffeine (200 mg + 100 mg), tolfenamic acid + metoclopramide (200 mg + 10 mg) and placebo were studied in 49 migraine patients (3 men, 46 women) in a double-blind randomized cross-over study comprising 482 migraine attacks. The patients were allowed to take either one or two capsules of each preparation for an attack. Additional drugs were allowed after 3 h. Parameters characterizing the effects and side-effects of the drugs were registered. Tolfenamic acid and its combinations were found to be effective in the treatment of acute migraine, but caffeine and metoclopramide alone did not differ from placebo. Combination with metoclopramide was better than tolfenamic acid alone as judged by the smaller dose needed and the intensity of attack. Between tolfenamic acid alone and its caffeine combination there were no statistically significant differences.

Adult↗

Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.

In two placebo-controlled, double-blind, randomized trials scopolamine (0.3 mg) alone or combined with ephedrine (25 mg) was tested for its effectiveness in the prevention of seasickness during 24 h at sea and of motion sickness in rotating chair tests in a laboratory. Scopolamine was effective both alone and in combination with ephedrine, which supports the hypothesis on central cholinergic overactivity in the pathogenesis of motion sickness. Ephedrine did not markedly increase the effectiveness of scopolamine. Side-effects were slight and did not disturb the operating ability of the volunteers.

Adult↗

Comparison of activated charcoal and ipecac syrup in prevention of drug absorption.

The efficacy of activated charcoal and ipecac syrup in the prevention of drug absorption was studied in 6 healthy adult volunteers, using a randomized, cross-over design. Paracetamol 1000 mg, tetracycline 500 mg and aminophylline 350 mg were ingested on an empty stomach with 100 ml water. Then, after 5 or 30 min, the subjects ingested, either activated charcoal suspension (50 g charcoal), syrup of ipecac, or, only after 5 min, water 300 ml. Activated charcoal, given either after 5 or 30 min, significantly (p less than 0.01 or less 0.05) reduced the absorption of these 3 drugs measured, for example as AUC0-24 h. Syrup of ipecac caused emesis on each occasion, with a mean delay of 15 min. When ipecac was given 5 min after the drugs, its effect on absorption was significant, but when it was given after 30 min only the absorption of tetracycline was reduced. Activated charcoal was significantly (p less than 0.05) more effective than ipecac in reducing drug absorption when given at the same time points. In cases of acute intoxication, depending on the quality and quantity of the drugs ingested, the relative efficacy of charcoal and ipecac may be somewhat different from that observed in the present study. Despite its emetic action, however, ipecac syrup is not very effective in preventing drug absorption and, in general, activated charcoal should also be given after induced emesis or gastric lavage.

Acetaminophen↗

Calcium, vitamin D and anabolic steroid in treatment of aged bones: double-blind placebo-controlled long-term clinical trial.

In a double-blind trial, 327 patients (57 men) over 65 (mean age 79.5) years received all possible combinations of calcium carbonate 3 g, vitamin D3 1000 iu, methandienone 2.5 mg and/or placebos daily for 9 months. The higher incidence of bone fractures in the placebo group was not significant. Serum calcium, phosphorus, creatinine, aspartate aminotransferase and alkaline phosphatase were followed: the greatest changes occurred with methandienone, which thus reduced osteoporotic activity and increased the muscular mass most effectively; calcium carbonate had the poorest effect. Surprisingly, coronary mortality was higher among those taking all three active substances. With two treatments the increase was not significant, but when both the groups receiving a combination of any two of the treatments were compared with those taking only one or neither of these two treatments, a significant increase in coronary deaths was seen, most significant (P less than 0.001) in those receiving vitamin D3 and methandienone.

Aged↗

Effects of nonsteroidal anti-inflammatory drugs on rat gastric mucosal phosphodiesterase activity.

In the present study, the effects of acetylsalicylic acid, diclofenac, ibuprofen, indomethacin, naproxen, phenylbutazone, proquazone, fluproquazone (RF 46-790 N), sulindac (sulfoxide and sulfide forms) and tolfenamic acid were compared on rat gastric mucosal cyclic nucleotide phosphodiesterases (PDEs). Some of the drugs inhibited PDEs effectively, the Ki values being clearly lower than those of theophylline. Mostly the type of inhibition was apparently competitive. Acetylsalicylic acid and ibuprofen were ineffective. No unambiguous correlation between the inhibition of mucosal PDEs and clinically observed gastric irritation was found. However, the inhibition of PDEs may modulate gastric side-effects of NSAIDs.

3',5'-Cyclic-AMP Phosphodiesterases↗

Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.

In seasickness, the central cholinergic-noradrenergic balance is disturbed. Capsules of identical appearance--containing scopolamine hydrobromide 0.3 mg, scopolamine hydrobromide 0.3 mg + ephedrine hydrochloride 25 mg, or placebo--were given prophylactically three times daily to 30 naval cadets during a crossing. In this randomized, double-blind trial the superiority of scopolamine and scopolamine + ephedrine over placebo was confirmed. Ephedrine did not clearly increase the effectiveness of scopolamine. One subject in the scopolamine group and one in the placebo group interrupted the treatment. The symptoms of seasickness as well as the number of side-effects of the drugs decreased on the third day of the study. Scopolamine alone or in combination with ephedrine proved useful in the prevention of seasickness in young healthy male volunteers.

Adult↗

Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: a controlled field trial among young adults and high-risk patients.

The usefulness of amantadine in the protection of humans against influenza A (H1N1) virus was evaluated in a double-blind field trial with 555 volunteers in Finland in the winter of 1978. Three populations--patients in a general hospital, adults in a home for the aged, and two groups of military conscripts--were chosen. Epidemic influenza occurred only in the two groups of conscripts: the incidence of serologically verified influenza was 66% and 83% in the groups that received placebo and 43% and 51% in the groups that received amantadine, giving protection rates of 36% (P = 0.05) and 39% (P = 0.001). The evaluation of the effect of amantadine on the occurrence of illness was obscured by concomitant adenoviral infections that caused influenza-like symptoms. No clear difference in the occurrences of side effects was observed between the placebo and amantadine-treated groups; however, a significantly greater number of participants who took 200 mg of amantadine/day (16.9%) stopped medication during the trial as compared with the placebo groups (7.6%) (P < 0.02).

Adult↗

Tolfenamic acid in ankylosing spondylarthritis: a double-blind comparison to indomethacin.

The randomized, double-blind trial was carried out with 50 patients suffering from ankylosing spondylarthritis and belonging all to type B27 in the HLA system. Tolfenamic acid (600 mg daily) was effective as judged by subjective and numerous objective parameters and was preferable to indomethacin (75 mg daily). Indomethacin caused side effects more frequently than tolfenamic acid. In the indomethacin group 16% of the patients interrupted the 6-month trial because of gastrointestinal complications. No discontinuation of treatment owing to adverse effects of tolfenamic acid occurred. Tolfenamic acid offers one new and good alternative for the medical treatment of ankylosing spondylarthritis.

Adult↗

A comparative, double-blind study on tolfenamic acid in the treatment of rheumatoid arthritis.

Sixty patients with diagnosed rheumatoid arthritis were treated at random with tolfenamic acid, a new nonsteroid anti-inflammatory analgesic, in a daily dose of 600 mg, or with phenylbutazone 300 mg or acetylsalicylic acid 1,500 mg daily. Both the patients and the physician found that tolfenamic acid had a clearly better effect than phenylbutazone or the low-dose acetylsalicylic acid used as a control. Tolfenamic acid and acetylsalicylic acid were well tolerated. Serious side-effects (leukopenia and thrombocytopenia in one case, hematemesis and melena in another) only occurred in those patients who received phenylbutazone.

Administration, Oral↗

Tolfenamic acid in the treatment of rheumatoid arthritis.

In an open trial of three months' duration the clinical effect of tolfenamic acid, a new nonsteroid anti-inflammatory analgesic, was found to be good in 85 patients suffering from rheumatoid arthritis. Both subjective and objective parameters clearly improved, and corticoid therapy could be abandoned by 21% of the patients. Tolfenamic acid was for the most part better than or as good as, the previous medication by which the disease had been brought to a stabile state. Side-effects were mild, no severe adverse reactions were observed which could be definitely attributed to tolfenamic acid.

Administration, Oral↗

Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor.

Plasma concentrations of levodopa were determined after therapeutic oral levodopa-carbidopa doses. The wide fluctuations observed in plasma levodopa levels could be considerably reduced by the addition of a slow release levodopa preparation. This kind of combination medication was given to 15 parkinsonian patients, whose earlier therapy had proved inadequate. With the combination medication, levodopa-carbidopa, on an average 420 mg/42 mg combined with 950 mg of levodopa in slow release form, a statistically significant improvement in parkinsonian signs could be achieved without any worsening of the side effects. The results suggest that parkinsonian patients may tolerate much higher daily levodopa doses if the fluctuations in plasma levels of the drug can be diminished.

Adult↗

Hepatic drug-oxidizing enzyme systems and urinary D-glucaric acid excretion in patients with congestive heart failure.

Drug-oxidizing enzyme systems in liver biopsy samples and the urinary excretion of D-glucaric acid were studied in two different groups of patients with cardiac insufficiency. 2. In one group of six patients, the activities of drug-metabolizing enzymes had decreased considerably as compared with the control values, but in four liver samples from patients treated with oral hypoglycaemic agents for their diabetes, activities were higher than in control samples from ten patients. 3. In the other group of seven patients, the urinary excretion of D-glucaric acid (isolated by ion-exchange chromatography) was 60% lower than in the control group of nine humans, whereas in four patients taking antiepileptic agents excretion rate was higher than control values. 4. Because the age distribution was markedly different between cardiac insufficiency and control groups, it is difficult to conclude, if the impairment of drug metabolism was a consequence of the old age or of the disease process. However, drug-oxidizing enzyme systems seem to be inducible also in old age. 5. The results support further the opinion that the urinary excretion of D-glucaric acid may be one useful index in assessing an individual's capacity to metabolize foreign compounds especially in the patients with lowered drug metabolizing capacity.

Adult↗

Clinical trial with an experimental taurine derivative, taltrimide, in epileptic patients.

The antiepileptic effect, effects on EEG, and tolerability of taltrimide, a new taurine derivative, were studied in this open clinical trial in 27 patients with severe epilepsy resistant to conventional drugs. After the 2-week control phase, taltrimide was given in gradually increasing doses up to 4.0 g/day--this dose used for 12 days. Taltrimide was given over 4 weeks and it was gradually withdrawn over 2 weeks. The frequency of seizures increased statistically significantly during the trial with increasing dose of taltrimide and decreased again in the withdrawal phase of the trial. Of six dropouts, one had status epilepticus, and in two patients increased number or severity of seizures necessitated withdrawal of taltrimide. There were no changes in EEG recordings or in laboratory data for safety evaluation. Taltrimide penetrated well through the blood-brain barrier, with the concentration of its main metabolite, phthalimidoethanesulphonamide, in cerebrospinal fluid, about half that in serum. The concentration of phenytoin increased statistically significantly, and there was a significant decrease in serum carbamazepine concentration during the taltrimide treatment. The anticonvulsive effect of taltrimide observed in animal experiments could not be confirmed in this study; in contrast, the seizures increased statistically significantly during taltrimide treatment. The reason for this remains obscure. The doses used, the significant drug interactions, or the patient material seemingly do not explain totally the noticed increase in seizure frequency. One explanation may be that taltrimide has proconvulsive properties in humans.

Adult↗

Effects of taltrimide, an experimental taurine derivative, on photoconvulsive response in epileptic patients.

Taltrimide is a lipophilic taurine derivative with definitive anticonvulsive effects in experimental epilepsy models. In this study, taltrimide was administered for 6 days, and the effects of the treatment on photoconvulsive response in EEG in eight epileptic patients were evaluated. Discharges provoked by intermittent photic stimulation (IPS) were increased by greater than 50% in four patients after taltrimide treatment. Only one patient had reduction of sensitivity. There was only a slight change in discharges after hyperventilation and no change in spontaneous paroxysms. The effects of taltrimide on photosensitivity appear to be rather specific. The study does not reveal anticonvulsive effects of taltrimide in humans.

Animals↗

Correlations between cytochrome P-450 and oxidative metabolism of benzo[a]pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo.

Cytochrome P-450 content was correlated to aryl hydrocarbon hydroxylase and 7-ethoxycoumarin O-de-ethylase activities in human liver biopsy samples in vitro. Antipyrine half-life and clearance were measured in the same patients in vivo. The results were compared with data obtained in rat liver in vitro. The correlation of cytochrome P-450 content with aryl hydrocarbon hydroxylase activity in human liver biopsy samples was relatively good (r = 0.75, p < 0.001), but that with 7-ethoxycoumarin O-de-ethylase activity was much poorer (r = 0.42, p < 0.001). The good correlation between cytochrome P-450 content and aryl hydrocarbon hydroxylase activity in biopsy samples from patients with widely varying hepatic disease processes, exposure to inducers, history of cigarette smoking, etc., is in contrast with the data obtained in the rat, where the corresponding correlation in a population treated with different inducers and inhibitors was rather poor (r = 0.37, p < 0.01). This poor correlation was caused mainly by the nonequal effects of polycyclic aromatic hydrocarbons on cytochrome P-450 and aryl hydrocarbon hydroxylase. Cigarette smoking was not found to induce human liver drug or carcinogen metabolism. Aryl hydrocarbon hydroxylase activity in vitro and antipyrine half-life or clearance in vivo were correlated (r = 0.36, p < 0.01 and r = 0.35, p < 0.01, respectively), indicating a weak, but statistically significant association between these parameters. This study suggests that correlations between in vitro and in vivo measurements of drug metabolism are not strong enough for the tests to be used as predictive tests in experimental or clinical research.

7-Alkoxycoumarin O-Dealkylase↗